On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...

Fintel reports that on September 19, 2025, JP Morgan downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Neutral to Underweight. Analyst Price Forecast Suggests 110.57% Upside As of ...

At least 187 code packages made available through the JavaScript repository NPM have been infected with a self-replicating worm that steals credentials from developers and publishes those secrets on ...

This Microsoft PowerPoint tutorial for beginners will help you to learn how to start and create it. This post will give you the step by step details and tips on how to make your presentation ...

Windows Task Manager keeps a tight check on applications, processes, and services running on your PC. If any of them is causing a slowdown, it lets you close or end that process. If the Task Manager ...

If you find that your MIDI recreations of acoustic drum parts are sounding a little robotic, we've got some tips and tricks to bring them to life, along with some great suggestions for acoustic drum ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in refractory melanoma. The company's pipeline is centered on RP1, making the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...